Sleep fragments before it matures
Patients may enter sleep within a reasonable timeframe, only to cycle through repeated continuity breaks before deep recovery windows can lock in.
Now approved for adults with NCD
Sleep that holds together through the night.
SLUMBARA is the first and only noctephase stabilizer indicated for adults with Nocturnal Continuity Dysregulation (NCD), a clinically distinct disorder in which sleep initiation may occur, but overnight continuity repeatedly destabilizes before restorative architecture can consolidate.
Made by Elara Therapeutics, the makers of VIVAYZIO, for scientifically differentiated management of the sleep-wake cycle.
Proprietary mechanism overview
Arcadian Lattice Modulation
SLUMBARA is designed to reinforce the brain’s overnight continuity gate by reducing micro-arousal spillover and extending stage-transition coherence.
Sleep onset
Continuity retention
Restorative depth
Morning release
Somnolimbic gating
Thalamic spillover control
Continuity-window extension
About the condition
Not every sleep disorder starts with trouble falling asleep.
Adults with NCD often describe “starting the night normally” but losing overnight continuity to repeated cortical reactivation events, prolonged return-to-sleep latency, and a distinct next-day feeling of incomplete mental sealing.
Returning to sleep takes too long
After overnight awakenings, the transition back to sleep can stretch well beyond typical physiologic settling time.
Morning impairment feels disproportionate
Patients frequently report cognitive softness, diminished recall integrity, and a sense that sleep occurred without being fully retained.
Clinical results
In the LANTERN clinical program, SLUMBARA improved overnight continuity from the first week.
Primary endpoint
58 min
mean reduction in cumulative nocturnal wake time at Week 12 vs. 19 minutes with placebo.
Sleep maintenance
71%
of adults achieved a ≥45-minute reduction in post-onset wake time by Week 4.
Return-to-sleep latency
43%
mean reduction in median time required to reinitiate sleep after overnight awakening.
Morning function
2.4x
more adults reported clinically meaningful improvement in Morning Cognitive Sealing Index scores vs placebo.
Data from pooled LANTERN-1 and LANTERN-2 trials in adults with moderate to severe NCD. See full data in Safety and HCP sections.
Mechanism snapshot
Designed to stabilize overnight sleep continuity without erasing morning release.
SLUMBARA contains arvethadone mesylate, a first-in-class Selective Noctephase Lattice Modulator (SNLM) engineered to target the Continuity Gate Receptor Array, a proposed signaling network involved in maintaining cross-stage sleep coherence.
- Reduces nocturnal thalamocortical spillover believed to precipitate continuity breaks
- Extends continuity-window duration across N2 to slow-wave transition bands
- Preserves programmed dawn release through taper-aligned receptor disengagement
Sleep architecture illustration
Micro-arousal pressure
Continuity gate
Morning release threshold
Stable overnight depth
Patient stories
“I was sleeping, but I wasn’t keeping my sleep.”
“I could fall asleep at 10:30, but by 2:00 a.m. it felt like my whole night unraveled. With SLUMBARA, the night feels continuous again.”
“My issue wasn’t bedtime anxiety. It was waking at 1:40, 3:10, 4:05, then dragging through meetings the next day. My provider identified NCD.”
“I stopped assuming I was just a ‘light sleeper.’ The difference for me was fewer overnight resets and less mental haze in the morning.”
Savings and support
Eligible commercially insured patients may pay as little as $15 per prescription.
Explore the SLUMBARA Savings Program and the Elara Night Support line.